An Introduction to Genitourinary Cancer
Genitourinary cancers incorporate the sub-specialities of prostate, kidney, bladder and testicular cancer. Advances in immunotherapies, targeted therapies and combination therapies have improved patient outcomes over recent years.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes, view our expert-led learning activities.
Genitourinary Cancer Content
Neal Shore, AACR 2022: KEYNOTE-992 a Phase 3 Study of Pembrolizumab in Muscle-invasive Bladder Cancer
touchONCOLOGY were delighted to talk with Dr. Neal Shore (GenesisCare; Carolina Urologic Research Center, Myrtle Beach, SC, USA) to discuss the phase 3 study of pembrolizumab plus chemoradiotherapy in the treatment of muscle-invasive bladder cancer. The abstract ‘KEYNOTE-992: A randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent […]
Kim Chi, ASCO GU22: First Results of the Phase III MAGNITUDE Study
Dr Kim Chi (The University of British Columbia, Vancouver, BC, Canada) summarises the first results of the phase 3 MAGNITUDE (NCT03748641) study of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with metastatic castration-resistant prostate cancer with and without homologous recombination repair gene alterations. Abstract: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012 Questions What is […]
Sexual Function of Men Undergoing Active Prostate Cancer Treatment Versus Active Surveillance: Results of the Europa Uomo Patient Reported Outcome Study
touchREVIEWS in Oncology & Haematology. 2022;18(1):88–94
Treatment for prostate cancer impacts the health-related quality of life of men. Patient-reported outcome (PRO) data from prospective, investigator-initiated clinical trials have shown that effects are seen on the urinary, bowel, and sexual function domains and, to a lesser extent, on the general quality of life (QoL) of men.1–5 In these clinical studies, patients reported […]
Simon Crabb, ASCO GU22: Final Analysis of the ATLANTIS Rucaparib Arm Assessing PARP Inhibitors for Metastatic Urothelial Carcinoma
touchONCOLOGY were joined by Dr Simon Crabb (Southampton University, UK) to discuss his presentation on the rucaparib arm of the ATLANTIS study, a randomized, double blind, biomarker selected, phase II clinical trial of maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma. Questions What is the rationale for the use of PARP inhibitors in the […]
Petros Grivas, ASCO GU22: Current Unmet Needs in the Treatment of Metastatic Urothelial Cancer
touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens. Question What are the current unmet educational needs in the treatment of metastatic […]
Petros Grivas, ASCO GU22: Results From Cohort 3 of the TROPHY-U-01 Study
touchONCOLOGY are joined by Dr Petros Grivas (University of Washington Medicine, Seattle, WAS, USA) to discuss results from Cohort 3 of the TROPHY-U-01 Study: Sacituzumab govitecan (SG) in combination with pembrolizumab in patients with metastatic urothelial cancer who progressed after platinum-based regimens. Questions What is the rationale for the combination of immune checkpoint inhibitors and […]
Morgan Rouprêt, ESOU22: What Have We Learned From the COVID-19 Pandemic?
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss what we have learned from the COVID-19 pandemic, how this has impacted the care of cancer patients and what we can do to move forward. Questions What was the impact of the COVID-19 pandemic on […]
Morgan Rouprêt, ESOU22: Impact of Immune Checkpoint Inhibitors on the Treatment of Bladder, Prostate and Kidney Cancer
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss the impact of immune checkpoint inhibitors on the treatment of bladder cancer, and other exciting therapeutic advances. Questions How have immune checkpoint inhibitors changed the treatment landscape for bladder cancer? (00:35-03:35) What […]
Morgan Rouprêt, ESOU22: Highlights from the Conference
touchONCOLOGY are joined by the EAU Section of Oncological Urology (ESOU) Chairman Professor Morgan Rouprêt to discuss his highlights from the 2022 conference. Questions Could you tell us a little about the this year’s EAU Section of Oncological Urology (ESOU22) and how well it went? (00:34-01:42) What were this […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!